These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23727860)

  • 21. Genetics: ZBTB7A suppresses castration-resistant prostate cancer.
    Razzak M
    Nat Rev Clin Oncol; 2013 Aug; 10(8):427. PubMed ID: 23774644
    [No Abstract]   [Full Text] [Related]  

  • 22. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
    Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
    Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
    Lieberman R
    Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
    [No Abstract]   [Full Text] [Related]  

  • 27. New hormonal therapies for castration-resistant prostate cancer.
    Mostaghel EA; Plymate S
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):625-42, x. PubMed ID: 21889725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the latest treatments for castration-resistant prostate cancer.
    Bishr M; Saad F
    Nat Rev Urol; 2013 Sep; 10(9):522-8. PubMed ID: 23797341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
    Nishiyama T
    Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
    Fahrenholtz CD; Beltran PJ; Burnstein KL
    Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
    Semenas J; Dizeyi N; Persson JL
    Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.